Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. Here, we show that therapeutically targeting the RNA helicase eIF4A with zotatifin, the first-in-class eIF4A inhibitor, exerts pleiotropic effects on both tumor cells and the tumor immune microenvironment in a diverse cohort of syngeneic triple-negative breast cancer (TNBC) mouse models. Zotatifin not only suppresses tumor cell proliferation but also directly repolarizes macrophages toward an M1-like phenotype and inhibits neutrophil infiltration, which sensitizes tumors to immune checkpoint blockade. Mechanistic studies revealed that zotatifin reprograms the tumor translational landscape, inhibits the translation of Sox4 and Fgfr1, and induces an interferon (IFN) response uniformly across models. The induction of an IFN response is partially due to the inhibition of Sox4 translation by zotatifin. A similar induction of IFN-stimulated genes was observed in breast cancer patient biopsies following zotatifin treatment. Surprisingly, zotatifin significantly synergizes with carboplatin to trigger DNA damage and an even heightened IFN response, resulting in T cell-dependent tumor suppression. These studies identified a vulnerability of eIF4A in TNBC, potential pharmacodynamic biomarkers for zotatifin, and provide a rationale for new combination regimens consisting of zotatifin and chemotherapy or immunotherapy as treatments for TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“eIF4A inhibitors, which target both isoforms, suppress translation of key oncogenes and have demonstrated antitumor activity in a variety of cancers (15, 17, 19–22).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, eIF4A1 is essential for embryonic development in mice (18) and in various cancer cell lines (19), whereas eIF4A2 is not.”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270 · cited 8×
“In summary, strategies to augment ICB and chemotherapy are needed for TNBC treatment.”
InfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454 · cited 2×
“…effect is not due to a nonspecific stress response, as zotatifin did not increase the phosphorylation of eIF2 α , an integrated stress response marker, nor M1-like tumor-inhibitory phenotype (35), zotatifin treatment increased the percentage of iNOS + cells as compared with the vehicle (Figure 2G).”
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
Cited by
Cencic, R., Im, Y. K., Naineni, S. K., Moustafa-Kamal, M., Jovanovic, P., Sabourin, V., Annis, M. G., Robert, F., Schmeing, T. M., Koromilas, A. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318093121 · Cited by 32
Pastena, P., Perera, H., Martinino, A., Kartsonis, W., & Giovinazzo, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052559 · Cited by 27
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Lizardo, M. M., Hughes, C. S., Huang, Y. Z., Shyp, T., Delaidelli, A., Zhang, H., Shaool, S. S., Renner, A. F., Burwag, F., Sayles, L. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1317 · Cited by 20
Yuan, X., Hao, X., Chan, H. L., Zhao, N., Pedroza, D. A., Liu, F., Le, K., Smith, A. J., Calderon, S. J., Lieu, N., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.182621 · Cited by 18
Self-citationBoyer, J. A., Rosen, E. Y., Sharma, M., Dorso, M. A., Mai, N., Amor, C., Reiter, J., Kannan, R., Gadal, S., Xu, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2424286122 · Cited by 20
Metadata
- Authors
- Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., Smith, A. J., Hamor, C., Safari, K., Savage, S., Zhang, B., Zhou, J., Solis, L. M., Hilsenbeck, S. G., Fan, C., Perou, C. M., & Rosen, J. M.
- Affiliations
- Baylor College of Medicine (US)
- Texas A&M Health Science Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rosen, Jeffrey M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2023-12-15
- Volume
- 133
- Issue
- 24
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10721161
- OpenAlex
- W4387909059
- Cited by
- 30
- References
- 68
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- NIH (CA16303-46)
- CPRIT (RP220468)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- eIF4A, triple-negative breast cancer, mRNA translation inhibition, interferon response, tumor immune microenvironment, macrophage polarization, neutrophil infiltration, immune checkpoint blockade, FGFR1, carboplatin, combination therapy, pharmacodynamic biomarkers
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Interferons, Cell Line, Tumor, Cell Proliferation, Mice, Tumor Microenvironment, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. https://app.cochat.ai/papers/10.1172/jci172503
- The paper
- Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., Smith, A. J., Hamor, C., Safari, K., Savage, S., Zhang, B., Zhou, J., Solis, L. M., Hilsenbeck, S. G., Fan, C., . . . Rosen, J. M. (2023). Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci172503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.